Price Cut For TB Prevention Drug Underscores Need To Identify, Treat Those At Risk Of Disease, Expert Writes In Opinion Piece

The Conversation: Preventing TB: a big drug price cut paves the way for global scale-up
Gavin Churchyard, honorary professor at the University of the Witwatersrand School of Public Health and CEO of the Aurum Institute

“…Talks to lower the price [of the antibiotic rifapentine] from US$45 to US$15 for a three-month course [to prevent tuberculosis (TB)] took more than a year to complete and involved Sanofi, Unitaid, and the Global Fund to Fight AIDS, Tuberculosis and Malaria, in collaboration with the Stop TB Partnership’s Global Drug Facility and the United States PEPFAR initiative. Now we — those of us who have been working to bring preventive therapy to the people whose lives depend on it — must roll up our sleeves and make it happen. … The [WHO TB prevention] guidelines now include three months of rifapentine and isoniazid taken weekly for people living in countries with a high TB burden. … All prevention programs must begin with finding the people who need TB preventive therapy…” (1/13).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.